Fig. 3.

Wild type, but not mutant HDAC3, confers sensitivity to microtubule-disrupting drugs in cancer cell lines that stably express antisense-HDAC3. Cell lysates from the indicated cell line were subjected to Western blot (A, B). (C) SNU387 cells that stably express antsense-HDAC3 (SNU387-As-HDAC3) were transiently transfected with control vector, HDAC3-Myc/His or HDAC3^S424A-Myc/His. At 24 h after transfection, cells were treated with or without celastrol (1 μM), taxol (1 μM) or vinblastine (100 nM) for 24 h, followed by Western blot analysis. (D) The same as C except that Malme3M-As-HDAC3 cell line was employed.